The federal government has recently identified the first 10 medications that will undergo direct price negotiations with manufacturers, as part of a significant new initiative to decrease prescription drug costs in Medicare. Among the list are widely used blood thinners Eliquis and Xarelto, as well as the cancer therapy Imbruvica. Additionally, drugs that treat diabetes, including Farxiga, Jardiance, and Januvia, are also included. These 10 drugs accounted for a total of $50.5 billion in spending in Medicare’s outpatient prescription drug program.
This announcement marks the beginning of a year-long process during which the government will collect data and seek public input, before engaging in price negotiations with the manufacturers regarding how much Medicare will pay for these drugs. This framework for negotiating prices was made possible by the Inflation Reduction Act, which was passed by Democrats in Congress last year. However, the fate of this new scheme remains uncertain, as critics from the drug industry and the Republican Party may attempt to weaken, block, or repeal it through legal action and new legislation.
If the negotiation process is successful, manufacturers will eventually agree to significant reductions in the prices of these drugs. These lower prices are expected to take effect by 2026, leading to savings for Medicare and the taxpayers who contribute to it. Medicare beneficiaries, especially seniors and individuals with disabilities, will also experience savings as they pay for drugs through premiums and out-of-pocket expenses. Currently, these out-of-pocket expenses can amount to hundreds or even thousands of dollars per year per drug.
Manufacturers have the option to refuse the government’s price offers; however, they would face severe financial penalties unless they choose to withdraw from Medicare and other public programs entirely. President Joe Biden stated that this initiative aims to address the issue where Americans pay more for prescription drugs compared to other major economies, while the pharmaceutical industry reaps record profits. Biden emphasized that millions of Americans are forced to choose between necessary medications and basic necessities such as food and housing, and he believes that these days are coming to an end.
Other economically advanced countries like France, Germany, and Japan have long used negotiation or regulation to control drug prices, resulting in significantly lower costs for their citizens. Although the U.S. government can now negotiate prices, its authority extends only to what Medicare pays and does not directly impact private insurance rates. However, the initiative’s scope is expected to expand over time, with the potential for more drugs to be selected for negotiation annually. Lawmakers in the future may also pass legislation to broaden the range of drugs subject to negotiation.
The opposition to direct negotiation from the drug industry and its allies is significant, as they argue that it is unconstitutional and will negatively impact innovation in the long run. Republicans share this sentiment and have previously endorsed repealing the government’s negotiation power. Nevertheless, the concept of negotiating drug prices has gained widespread support among voters, including Republican voters, as shown by various polls. Liberal and moderate Democratic leaders, as well as advocacy groups like AARP, also support the idea, underscoring its potential impact on older Americans’ financial stability and overall health.
President Biden intends to make these reforms a focal point of his reelection campaign. He plans to highlight opposition from both Republicans and the drug industry, while also advocating for the expansion of negotiation powers. Additionally, he aims to raise awareness of other measures to reduce drug prices for seniors, such as the phased implementation of a cap on out-of-pocket prescription expenses starting next year. As healthcare costs remain a top concern for U.S. voters, the issue is expected to be prominent during the 2024 election cycle.
The impact of negotiation on the drug industry remains uncertain, although it is likely that some manufacturers will experience a reduction in revenue. However, the industry is still rated highly, with a history of innovation and the ability to introduce new products and advance medicine. Medicare has long negotiated or set prices for other medical goods and services, so price negotiation for drugs represents a compromise. The law limits the number of drugs subject to negotiation, focusing on the highest spending drugs, and allows drug companies to set their own prices for years before negotiated prices take effect.
The list of drugs selected for negotiation largely aligned with predictions from analysts; however, one unexpected inclusion is a group of insulin products. Insulin is crucial for many people with diabetes, and the high prices set by the three companies controlling the market have been a cause for concern. The inclusion of insulin in the negotiation process signifies a significant step in addressing this issue.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
